Evidence map›Paper›PMID 33528731›Full record

ArticlePituitary2021

Neural network modeling for prediction of recurrence, progression, and hormonal non-remission in patients following resection of functional pituitary adenomas.

Shane Shahrestani, Tyler Cardinal, Alexander Micko, Ben A Strickland, Dhiraj J Pangal, Guillaume Kugener, Martin H Weiss, John Carmichael, Gabriel Zada

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Shane ShahrestaniDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. shanesha@usc.edu.ORCID http://orcid.org/0000-0001-7561-4590
Tyler CardinalDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Alexander MickoDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Ben A StricklandDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Dhiraj J PangalDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Guillaume KugenerDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Martin H WeissDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
John CarmichaelDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Gabriel ZadaDepartment of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFunctional pituitary adenomas (FPAs) cause severe neuro-endocrinopathies including Cushing's disease (CD) and acromegaly. While many are effectively cured following FPA resection, some encounter disease recurrence/progression or hormonal non-remission requiring adjuvant treatment. Identification of risk factors for suboptimal postoperative outcomes may guide initiation of adjuvant multimodal therapies.

methodsPatients undergoing endonasal transsphenoidal resection for CD, acromegaly, and mammosomatotroph adenomas between 1992 and 2019 were identified. Good outcomes were defined as hormonal remission without imaging/biochemical evidence of disease recurrence/progression, while suboptimal outcomes were defined as hormonal non-remission or MRI evidence of recurrence/progression despite adjuvant treatment. Multivariate regression modeling and multilayered neural networks (NN) were implemented. The training sets randomly sampled 60% of all FPA patients, and validation/testing sets were 20% samples each.

results348 patients with mean age of 41.7 years were identified. Eighty-one patients (23.3%) reported suboptimal outcomes. Variables predictive of suboptimal outcomes included: Requirement for additional surgery in patients who previously had surgery and continue to have functionally active tumor (p = 0.0069; OR = 1.51, 95%CI 1.12-2.04), Preoperative visual deficit not improved after surgery (p = 0.0033; OR = 1.12, 95%CI 1.04-1.20), Transient diabetes insipidus (p = 0.013; OR = 1.27, 95%CI 1.05-1.52), Higher MIB-1/Ki-67 labeling index (p = 0.038; OR = 1.08, 95%CI 1.01-1.15), and preoperative low cortisol axis (p = 0.040; OR = 2.72, 95%CI 1.06-7.01). The NN had overall accuracy of 87.1%, sensitivity of 89.5%, specificity of 76.9%, positive predictive value of 94.4%, and negative predictive value of 62.5%. NNs for all FPAs were more robust than for CD or acromegaly/mammosomatotroph alone.

conclusionWe demonstrate capability of predicting suboptimal postoperative outcomes with high accuracy. NNs may aid in stratifying patients for risk of suboptimal outcomes, thereby guiding implementation of adjuvant treatment in high-risk patients.

Indexed as

AdenomaPituitary NeoplasmsAcromegalyAdultHumansNeoplasm Recurrence, LocalNeural Networks, ComputerPituitary ACTH HypersecretionRetrospective StudiesTreatment OutcomeAdenomaFunctionalMachine learningPituitaryProgressionRecurrence

Identifiers

PMID33528731
OpenAlexW3126339458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.